Latest1 information on COVID-19

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT00352027

Age - N/A-21 Years Condition - Lymphoma: Hodgkin, Pediatric Radiology, Pediatric Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Official Title

Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma

Stanford Investigator(s)

Michael Link

Eligibility


Inclusion Criteria:

   - Patient is less than or equal to 21 years of age

   - Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma

   - Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal
   involvement (3 or more sites), or bulky mediastinal adenopathy.

Exclusion Criteria:

   - Patients with favorable risk features

   - Patients with unfavorable risk features

   - Patients who have received prior therapy for Hodgkin lymphoma.

View More
View Less

Intervention(s):

procedure: Radiotherapy

drug: Adriamycin®

drug: Vinblastine

drug: Nitrogen Mustard

drug: Cyclophosphamide

drug: Vincristine

drug: Bleomycin

drug: Etoposide

drug: Prednisone

biological: G-CSF

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine